The other bit of good news is some evidence emerging that the 640g is as good at preventing hypos in children as it is in adults. As far as I remember, all of the evidence of hypo prevention using the 640g SmartGuard algorithm was based on adult data.
At the last ADA meeting, Medtronic presented* the results from a small (40 subjects, 4 weeks of data) non-randomised study of home-use of the 640g. Although the study design wouldn't tick the boxes in terms of statistical power or design (it's not randomised; it's quite small) it did capture over 2,300 SmartGuard trigger events and, crucially, included paediatric users.
The key - for paediatric 640g pumpers and their parents - is that these results suggest that the 640g is just as good at preventing hypoglycemia in children as it is in adults - avoiding the low limit around 80-85% of the time (based on sensor glucose readings) both in the day and at night time:
I'm very aware that the 640g - or more specifically the Enhanced Enlite (Enlite 2) sensors combined with the Guardian 2 Link transmitter and 640g pump - are not working well for everyone (which kind of rules out effective use of SmartGuard), but I think this is encouraging news for those of us who committed to four years on the 640g.
* MiniMed 640g user Evaluation Study, ADA 2015, Presentation 1080P. The paediatric data were 672 triggers during the day and 338 at night time. This poster was first flagged to me during this month's Medtronic Bloggers and Advocacy meeting: Medtronic gave me travel expenses, coffee, lunch and the chance to catch up with some wonderful fellow bloggers and T1D advocates, but did not ask that any particular news be shared or a particular viewpoint be taken.
No comments:
Post a Comment